Specialty Pharma Journal Specialty, Precision & Technology
GAITHERSBURG, Md., Aug. 13, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to acquire PaxVax, a company focused on specialty vaccines that protect against existing and emerging infectious diseases, for an all-cash consideration of $270 million. PaxVax is majority owned …
Tag Archives: Infectious Diseases
August, 2018
January, 2017
-
16 January
FDA Grants Redhill Biopharma’s Treatment for Nontuberculous Mycobacteria Infections QIDP Fast Track Designation
RHB-104 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA for the treatment of Nontuberculous Mycobacteria (NTM) Infection Under FDA’s Generating Antibiotic Incentives Now (GAIN) Act, QIDP designation allows for Fast-Track status and Priority Review, potentially leading to a shorter NDA review time by the FDA, …
August, 2016
-
26 August
Special Report Documents Zika Virus’ Impact on the Fetal Brain
BOSTON – In a special report released August 23 in the journal Radiology, a team of researchers including Deborah Levine, MD, Director of Obstetric & Gynecologic ultrasound at Beth Israel Deaconess Medical Center (BIDMC) and professor of radiology at Harvard Medical School (HMS), documented the brain abnormalities associated with congenital …
-
19 August
Xenetic Biosciences Partners with Excivion for Development of Novel Combined Zika and Dengue Vaccine
LEXINGTON, Mass.–(BUSINESS WIRE)–Xenetic Biosciences, Inc. (OTCQB: XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company developing next-generation biologic drugs and novel orphan oncology therapeutics, today announced that it has commenced a collaboration with Excivion Ltd. (“Excivion”) to develop a vaccine against Zika and dengue viruses. As part of the collaboration, Xenetic’s …
March, 2016
-
22 March
Pfizer Joins the Human Vaccines Project to Help Decode the Immune System
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today announced it will join the Human Vaccines Project (the Project), a public-private consortium focused on cross-sector collaboration to identify human immune responses associated with optimal vaccine protection. Insights gained will guide the development of potentially improved vaccines against diseases such as influenza, dengue, HIV …
February, 2016
-
24 February
FDA Accepts and Grants Priority Review to Allergan’s Avycaz sNDA
DUBLIN, Feb. 24, 2016 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s supplemental New Drug Application (sNDA) for AVYCAZ® (ceftazidime and avibactam). This filing will add important new clinical data to the current label …